Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Lantheus Holdings Inc | 19 |
| 2 | Cornell University | 16 |
| 3 | German Cancer Research Center | 10 |
| 4 | Novartis AG | 10 |
| 5 | Johns Hopkins University | 8 |
| 6 | Albert Ludwigs Universität Freiburg | 7 |
| 7 | University of California | 7 |
| 8 | Curium Pharma SAS | 6 |
| 9 | Amgen Inc | 5 |
| 10 | The University of Texas System | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 194 |
| 2 | A61P | Therapeutic activity (drug indications) | 140 |
| 3 | C07D | Heterocyclic compounds | 66 |
| 4 | C07B | General methods of organic chemistry | 61 |
| 5 | C07K | Peptides | 44 |
| 6 | G06T | 40 | |
| 7 | A61B | 33 | |
| 8 | C07F | Organometallic compounds | 31 |
| 9 | G16H | Digital health, healthcare informatics | 29 |
| 10 | C07C | Acyclic and carbocyclic compounds | 26 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Systems and methods for platform agnostic whole body image segmentation | 2023 | 7 | |
| Radiolabeled compounds targeting prostate specific membrane antigen | 2022 | 9 | |
| Systems and methods for platform agnostic whole body image segmentation | 2024 | 4 | |
| CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | 2023 | 5 | |
| INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | 2023 | Jiangsu Hengrui Medicine Co Ltd | 4 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 83 |
| 2017 | 97 |
| 2018 | 130 |
| 2019 | 162 |
| 2020 | 159 |
| 2021 | 142 |
| 2022 | 120 |
| 2023 | 75 |
| 2024 | 107 |
| 2025 | 35 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Jérémie Calais | University of California, Los Angeles | 26 |
| 2 | Ken Herrmann | Essen University Hospital | 23 |
| 3 | Wolfgang P. Fendler | Essen University Hospital | 23 |
| 4 | Uwe Haberkorn | Heidelberg University | 19 |
| 5 | Louise Emmett | St Vincent's Hospital Sydney | 18 |
| 6 | Francesco Ceci | University of Bologna | 16 |
| 7 | Tobias Maurer | Technical University of Munich | 15 |
| 8 | Markus Schwaiger | Technical University of Munich | 14 |
| 9 | Ali Afshar‐Oromieh | University Hospital Heidelberg | 14 |
| 10 | Matthias Eiber | Technical University of Munich | 13 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Gallium Ga-68 gozetotide?
Which organizations hold the most patents related to Gallium Ga-68 gozetotide?
What is the recent patent filing trend for this compound?
Who are the most prolific authors publishing on Gallium Ga-68 gozetotide?
What are the primary patent classification areas for compounds in this category?